Cytopia, Ltd.

Company gets green light for CYT997 trial

Published in Lab Law Weekly, May 27th, 2005

Up to 30 patients with advanced incurable solid-tumors are to be involved in clinical trials of a new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia, Ltd.

Cytopia Managing Director Dr. Kevin Healey said the company had obtained the necessary ethics approvals to begin clinical trials at the Royal Brisbane and Women's Hospital in association with the Queensland Institute of Medical Research and Q-Pharm Pty, Ltd. The tests will be supervised by leading ovarian oncologist, Dr. Paul Vasey, and medical oncologist, Dr. Jason Lickliter.

"In animal studies, CYT997 was highly effective in killing cancer cells including...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2005-05-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry